Therapy for filovirus infection

US10435461B2 · kind B2 · utility

Assignees

• Albert Einstein College of Medicine · US
• The Governing Council of the University of Toronto · CA
• The Government of the United States, as represented by the Secretary of the Army · US

Inventors

• Jonathan R. Lai · Dobbs Ferry, US
• Jayne F. Koellhoffer · New York, US
• Julia Frei · The Bronx, US
• Kartik Chandran · Brooklyn, US
• Sachdev Sidhu · Toronto, CA
• Gang Chen · Sammamish, US
• John M. Dye · Frederick, US
• Samantha Zak · Frederick, US

Key dates

• Filing date: Aug 6, 2015
• Grant date: Oct 8, 2019
• Expiry date: Aug 6, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.